Target autoimmune Cullinan Therapeutics is a clinical-stage biopharma focusing on autoimmune diseases and cancer using T cell engager technology. This presents opportunities to partner or co-develop targeted immunotherapies for autoimmune indications such as Sjögren's, lupus, and rheumatoid arthritis where their CLN-978 program is active.

Strategic partnerships Recent licensing and collaboration activity, including velinotamig licensing and a Genrix Bio collaboration for velinotamig, signals openness to external partnerships. This creates potential sales/playbook avenues for BD to propose co-development, out-licensing, or technology-sharing deals.

Financial strength With a funding level around several hundred million dollars and mature revenue in the tens of millions, Cullinan demonstrates financial runway favorable for joint-venture pilots, milestone-driven deals, and pharma partnerships that require capital for late-stage development.

Engagement channels The company actively participates in major conferences (ASCO, ASH, immunology forums) and hosts investor events, indicating accessible engagement points for sponsor meetings, clinical collaboration discussions, and visibility in the investor and pharma community.

Clinical momentum A pipeline focused on modality-agnostic targeted therapies and T cell engager platforms across autoimmune diseases positions Cullinan as a partner for late-stage asset opportunities, biomarker-driven programs, and fast-to-clinic collaboration in high-need indications.